Details
Stereochemistry | ACHIRAL |
Molecular Formula | C24H32N6O4 |
Molecular Weight | 468.5487 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CCCOCCN1C(=O)C(=NC2=C1C=C(N=C2)C3=CC=C(OC)N=C3)N4CCN(CCO)CC4
InChI
InChIKey=MNLNAGRCHNMKKJ-UHFFFAOYSA-N
InChI=1S/C24H32N6O4/c1-3-13-34-14-11-30-21-15-19(18-4-5-22(33-2)26-16-18)25-17-20(21)27-23(24(30)32)29-8-6-28(7-9-29)10-12-31/h4-5,15-17,31H,3,6-14H2,1-2H3
Molecular Formula | C24H32N6O4 |
Molecular Weight | 468.5487 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: O76074 Gene ID: 8654.0 Gene Symbol: PDE5A Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/26738812 |
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 01:41:48 GMT 2023
by
admin
on
Sat Dec 16 01:41:48 GMT 2023
|
Record UNII |
9CZX3Z9945
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Code | English | ||
|
Code | English | ||
|
Systematic Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
300000042473
Created by
admin on Sat Dec 16 01:41:48 GMT 2023 , Edited by admin on Sat Dec 16 01:41:48 GMT 2023
|
PRIMARY | |||
|
9CZX3Z9945
Created by
admin on Sat Dec 16 01:41:48 GMT 2023 , Edited by admin on Sat Dec 16 01:41:48 GMT 2023
|
PRIMARY | |||
|
24963293
Created by
admin on Sat Dec 16 01:41:48 GMT 2023 , Edited by admin on Sat Dec 16 01:41:48 GMT 2023
|
PRIMARY | |||
|
954138-07-9
Created by
admin on Sat Dec 16 01:41:48 GMT 2023 , Edited by admin on Sat Dec 16 01:41:48 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
Drugs: Bupivacaine(Primary), Epinephrine, Ketorolac, Morphine, Ropivacaine, Sodium chloride; Indication: Postoperative pain; Focus: Therapeutic Use; Most Recent Event: 28 Nov 2014 New trial record
|